Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00507728 · ClinicalTrials.gov registry record · Phase 2
Pharmacogenetics, Emotional Reactivity and Smoking
A Phase 2 study of Smoking Cessation and Tobacco Use Disorder, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 646
- Enrollment target
- 1
- Study location
NCT00507728 is a Phase 2 study of Smoking Cessation and Tobacco Use Disorder that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 646 participants, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00507728, a Phase 2 study of Smoking Cessation and Tobacco Use Disorder, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 646 participants
- Enrollment target
- 1
- Study location
Study Summary
The goals of this placebo-controlled randomized clinical trial were to evaluate the differences in emotional reactivity (peak startle response to affective stimuli) during a cessation attempt among smokers treated with bupropion, varenicline, or placebo, and to determine if these differences were moderated by genotype.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
- BEHAVIORAL Smoking Cessation Counseling
- DRUG Bupropion
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2005-12-08 |
| Est. Completion | 2019-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00507728
The ClinicalTrials.gov registry entry for NCT00507728 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 646 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (37% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00507728 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00507728 about?
NCT00507728 is a clinical study titled "Pharmacogenetics, Emotional Reactivity and Smoking". The goals of this placebo-controlled randomized clinical trial were to evaluate the differences in emotional reactivity (peak startle response to affective stimuli) during a cessation attempt among smokers treated with bupropion, varenicline, or placebo, and to determine if these differences were mo...
What is the current status of trial NCT00507728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 646 participants. The study started on 2005-12-08. Estimated completion is 2019-12-18.
What conditions does trial NCT00507728 study?
This clinical trial studies the following conditions: Smoking Cessation, Tobacco Use Disorder.
What interventions are being tested in trial NCT00507728?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG), Smoking Cessation Counseling (BEHAVIORAL), Bupropion (DRUG).
Who is sponsoring clinical trial NCT00507728?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00507728 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
RECRUITING · Phase 2
-
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
COMPLETED · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Suvorexant to Reduce Symptoms of Nicotine Use
COMPLETED · Phase 2
-
Provoked Craving Relief Study by NRT
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.